Abstract: The present invention relates to crystalline form V of a compound represented by chemical formula 1, a method for preparing same, and a pharmaceutical composition comprising same. Crystalline form V of the compound represented by chemical formula 1 according to the present invention may be characterized by an XRD pattern, a DSC profile, and/or a TGA profile.
| # | Name | Date |
|---|---|---|
| 1 | 202317073172-TRANSLATIOIN OF PRIOIRTY DOCUMENTS ETC. [27-10-2023(online)].pdf | 2023-10-27 |
| 2 | 202317073172-STATEMENT OF UNDERTAKING (FORM 3) [27-10-2023(online)].pdf | 2023-10-27 |
| 3 | 202317073172-PROOF OF RIGHT [27-10-2023(online)].pdf | 2023-10-27 |
| 4 | 202317073172-POWER OF AUTHORITY [27-10-2023(online)].pdf | 2023-10-27 |
| 5 | 202317073172-MARKED COPIES OF AMENDEMENTS [27-10-2023(online)].pdf | 2023-10-27 |
| 6 | 202317073172-FORM 13 [27-10-2023(online)].pdf | 2023-10-27 |
| 7 | 202317073172-FORM 1 [27-10-2023(online)].pdf | 2023-10-27 |
| 8 | 202317073172-DRAWINGS [27-10-2023(online)].pdf | 2023-10-27 |
| 9 | 202317073172-DECLARATION OF INVENTORSHIP (FORM 5) [27-10-2023(online)].pdf | 2023-10-27 |
| 10 | 202317073172-COMPLETE SPECIFICATION [27-10-2023(online)].pdf | 2023-10-27 |
| 11 | 202317073172-AMMENDED DOCUMENTS [27-10-2023(online)].pdf | 2023-10-27 |
| 12 | 202317073172-FORM 18 [30-10-2023(online)].pdf | 2023-10-30 |
| 13 | 202317073172-FORM 3 [24-05-2024(online)].pdf | 2024-05-24 |
| 14 | 202317073172-FORM 3 [05-05-2025(online)].pdf | 2025-05-05 |